Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/26/2021 | $2.50 → $3.50 | Buy | HC Wainwright & Co. |
| 6/24/2021 | $3.00 | Overweight | Cantor Fitzgerald |
VANCOUVER, British Columbia, Jan. 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – Consumer healthcare markets hit a massive $362 billion entering 2026, but smart money is shifting toward regulatory certainty rather than just market size[1]. Modern health organizations are using aggressive buyouts as a primary 2026 strategy to secure high-tech efficiency while navigating intense federal scrutiny and capital limits[2]. In this high-stakes environment, companies with a clear and proven path through federal guidelines are capturing the most attention, including Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Canopy Growth (NASDAQ:CGC) (TSX:WEED), Definium Therap
Company on track to report topline results early in the second quarter of 2026Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomizedNo drug discontinuations, excessive sedation, loss of consciousness, or drug-related SAEs reportedStudy is no longer screening new participantsSALT LAKE CITY, Jan. 12, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced the completion of a scheduled independent Data Safety Monitoring Board review of its ongoing Phase 3 clinical trial evaluating LPCN
Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline results on track for the second quarter of 2026SALT LAKE CITY, Dec. 16, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced 80% completion of enrollment in the ongoing Phase 3 clinical trial evaluating LPCN 1154 (oral brexanolone) for the rapid relief treatment of PPD, with 66 of the 80 planned study participants randomized. In addition, the second of two independent Data Safety Monitoring Board reviews is planned for early-January 2026. Following the
HC Wainwright & Co. reiterated coverage of Lipocine with a rating of Buy and set a new price target of $3.50 from $2.50 previously
Cantor Fitzgerald initiated coverage of Lipocine with a rating of Overweight and set a new price target of $3.00
HC Wainwright & Co. reiterated coverage of Lipocine with a rating of Buy and set a new price target of $2.50 from $3.00 previously
4 - Lipocine Inc. (0001535955) (Issuer)
4 - Lipocine Inc. (0001535955) (Issuer)
4 - Lipocine Inc. (0001535955) (Issuer)
SC 13G/A - Lipocine Inc. (0001535955) (Subject)
SC 13G/A - Lipocine Inc. (0001535955) (Subject)
SC 13G - Lipocine Inc. (0001535955) (Subject)
Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Approval' on 03/28/2022. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form
Submission status for LIPOCINE INC's drug TESTOSTERONE UNDECANOATE (ORIG-1) with active ingredient TESTOSTERONE UNDECANOATE has changed to 'Tentative Approval' on 12/08/2020. Application Category: NDA, Application Number: 208088, Application Classification: Type 3 - New Dosage Form
8-K - Lipocine Inc. (0001535955) (Filer)
8-K - Lipocine Inc. (0001535955) (Filer)
SCHEDULE 13G - Lipocine Inc. (0001535955) (Subject)
Industry veterans Jill M. Jene, Ph.D. and Spyros Papapetropoulos M.D. Ph.D. appointed to Board SALT LAKE CITY, April 11, 2022 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on neuroendocrine and metabolic disorders, announced today the appointment of Jill M. Jene, Ph.D. and Spyros Papapetropoulos, M.D., Ph.D. to its board of directors. "We are very pleased to welcome Jill Jene and Spyros Papapetropoulos to our board of directors. Each of them brings a wealth of relevant expertise," said Mahesh V. Patel, Ph.D., Chairman and CEO of Lipocine. "J
SALT LAKE CITY, Nov. 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the third quarter ended September 30, 2025 and provided a corporate update. Neuroactive Steroids (NAS) LPCN 1154 for Postpartum Depression (PPD) LPCN 1154 (oral brexanolone) is a non-invasive, rapid onset, oral formulation of the neuroactive steroid brexanolone that Lipocine is developing for the treatment of PPD.A Phase 3 safety and ef
SALT LAKE CITY, Aug. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced financial results for the second quarter ended June 30, 2025 and provided a corporate update. Neuroactive Steroids LPCN 1154 (oral brexanolone product candidate) is a non-invasive, 48-hour treatment option targeted for rapid symptom relief of postpartum depression (PPD), a serious unmet medical need. LPCN 1154 could have advantages with respect to limitat
SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2025 and provided a corporate update. Neuroactive Steroids Lipocine has initiated an outpatient Phase 3 safety and efficacy study of LPCN 1154, a non-invasive, rapid onset, oral formulation of brexanolone for the treatment of postpartum depression (PPD). Dosing of the first patient is anticipated in the s